No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AVD240517C10000
- 0.10
- 0.000.00%
15min DelayClose May 15 12:23 ET
0.10High0.10Low
0.10Open0.10Pre Close1 Volume213 Open Interest10.00Strike Price10.00Turnover184.15%IV15.56%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.1713Delta0.2198Gamma87.40Leverage Ratio-0.0742Theta0.0001Rho14.97Eff Leverage0.0016Vega
Intraday
- 5D
- 1D
News
Express News | American Vanguard Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results
NVAX, GRPN and MVIS Among Mid-day Movers
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
American Vanguard | 10-Q: Quarterly report
Earnings Flash (AVD) AMERICAN VANGUARD CORPORATION Posts Q1 Revenue $135.1M, Vs. Street Est of $141.9M
04:30 PM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (AVD) AMERICAN VANGUARD CORPORATION Posts Q1 Revenue $135.1M, vs. Street Est of $141.9M
Express News | American Vanguard Q1 2024 GAAP EPS $0.06 Misses $0.12 Estimate, Sales $135.00M Miss $141.90M Estimate
Comments
Vanguard's decision to not offer bitcoin ETFs has frustrated some customers, leading to actions like Julian Fahrer, co-founder and CEO at Apollo, transferring his 401(k) from Vanguard to Fidelity. Analysts suggest institutions not offering bitcoin trading may see user outflows.
Vanguard's refusal to offer bitcoin ETFs, seen as unsafe, has irked some crypto enthusiasts. Despite some Wall Street brokerages' resistance, new funds' trading volume indicates strong market interest.
With earnings per share shrinking 26% annually over the last five years and dividend payments declining 1.5% yearly over the past decade, the company's stock is a less desirable dividend investment.
$2seventy bio(TSVT.US$ analyst target price 8.2
$OptiNose(OPTN.US$ all analysts target price 3
$Arcutis Biotherapeutics(ARQT.US$ avg target price 9.6 (low 4, high 20)
Some of its chart show something good is going to happen, hope no more prank coming from these.
Vanguard and Blackrock also added position on September... ARQT has Vanguard only added position...
still have to wait FDA result though, nothing can be assured. the FDA tracker dot com only provide the...
$OptiNose(OPTN.US$ all analysts target price 3
$Arcutis Biotherapeutics(ARQT.US$ avg target price 9.6 (low 4, high 20)
Some of its chart show something good is going to happen, hope no more prank coming from these.
Vanguard and Blackrock also added position on September... ARQT has Vanguard only added position...
still have to wait FDA result though, nothing can be assured. the FDA tracker dot com only provide the...
1
4
Read more